Traumatic brain injury (TBI) is a major cause of disability and death globally, but medications have generally failed to benefit patients. A new study found that memantine, a drug that is used to treat dementia associated with Alzheimer’s disease, may be a promising therapy.
The study examined the effect of memantine on blood levels of neuron-specific enolase (NSE), a marker of neuronal damage, and the Glasgow Coma Scale (GCS) in patients with moderate TBI. The GCS is the most common scoring system used to describe the level of consciousness in a person following a TBI.
Patients with moderate TBI who received memantine had significantly reduced blood levels of NSE by day 7 and marked improvements in their GCS scores on day 3 of the study.
The study is published in The Journal of Clinical Pharmacology.
Link to Study: http://onlinelibrary.wiley.com/doi/10.1002/jcph.980/full
The Journal of Clinical Pharmacology (JCP) is the flagship publication of the American College of Clinical Pharmacology. Published since 1961, the journal has been providing readers with access to original research, special reviews, commentaries, and case reports on all phases of drug development. A monthly, international peer-reviewed journal, The Journal of Clinical Pharmacology (JCP) transitioned to an online-only format beginning in 2013.